Table 6 Comparison of microbiological data susceptibility tests between our study and Camargo et al. study [1]
From: Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
Variables | n(%) |
|---|---|
2002 a 2007* | |
Candida albicans (n = 27) | |
Amphotericin B (n = 27) | |
Susceptible | 27 (100.0) |
Fluconazole (n = 27) | |
Susceptible | 27 (100.0) |
Candida non-albicans (n = 51) | |
Amphotericin B (n = 51) | |
Susceptible | 51 (100.0) |
Fluconazole (n = 51) | |
Susceptible | 42 (82.3) |
2012 a 2016** | |
Candida albicans (n = 42) | |
Amphotericin B (n = 40) | |
Susceptible | 40 (100.0) |
Fluconazole (n = 41) | |
Susceptible | 41 (100.0) |
Voriconazole (n = 41) | |
Susceptible | 41 (100.0) |
Caspofungin (n = 1) | |
Susceptible | 1 (100.0) |
Anidulafungin (n = 3) | |
Susceptible | 3 (100.0) |
Candida non-albicans (n = 73) | |
Amphotericin B (n = 72) | |
Susceptible | 72 (100.0) |
Fluconazole (n = 64) | |
Susceptible | 55 (85.9) |
Resistant | 3 (4.7) |
Intermediate | 6 (9.4) |
Voriconazole (n = 64) | |
Susceptible | 63 (98.4) |
Intermediate | 1 (1.6) |
Caspofungin (n = 10) | |
Susceptible | 9 (90.0) |
ntermediate | 1 (10.0) |
Anidulafungin (n = 11) | |
Susceptible | 8 (72.7) |
Intermediate | 3 (27.3) |